Chronic administration of SalA accelerates neural recovery by promoting endogenous neurogenesis and axonal sprouting, as well as by inhibiting neuronal apoptosis after ischemic stroke via the Wnt3a/β-catenin signaling pathway. This contributes to improved long-term outcomes in stroke. This evidence concerns the gene WNT3A and ischemic stroke.